BRANFORD, Conn., June 5 /PRNewswire-FirstCall/ -- CuraGen Corporation , a clinical-stage biopharmaceutical company focused on oncology, announced today that presentations will be made at two upcoming investor conferences.
Dr. Frank Armstrong, President and Chief Executive Officer of CuraGen will present at the 3rd Annual Bear Stearns Boston Biotech Confab on Thursday, June 7, 2007, at 11:25 a.m. Eastern time. The conference is being hosted at the Boston Marriott Copley Place in Boston, MA.
Dr. Armstrong will also present at the Needham & Company Sixth Annual Biotechnology and Medical Technology Conference on Thursday, June 14, 2007, at 11:30 a.m. Eastern time. The conference is being held at the New York Palace Hotel in New York, NY.
Access to a live webcast of the presentations will be available from the Investor Relations section of CuraGen’s website at http://www.curagen.com. A replay of the webcast will be available after the presentation and archived for 30 days thereafter.
About CuraGen
CuraGen Corporation is a dedicated clinical-stage biopharmaceutical company developing diverse approaches, including novel protein, antibody, antibody-drug conjugate and small molecule therapeutics for the treatment of cancer and for cancer supportive care. CuraGen is currently conducting clinical trials to investigate the potential of velafermin, belinostat and CR011-vcMMAE. By leveraging the drug development strengths cultivated over the years, CuraGen expects to make a difference by advancing its promising therapeutics to address the unmet medical needs of cancer patients. CuraGen Corporation is headquartered in Branford, Connecticut. For additional information please visit www.curagen.com.
CuraGen Contact: Glenn Schulman, Pharm.D. Director of Investor Relations gschulman@curagen.com (888) 436-6642 CRGN-G
CuraGen Corporation
CONTACT: Glenn Schulman, Pharm.D., Director of Investor Relations ofCuraGen Corporation, +1-888-436-6642, gschulman@curagen.com
Web site: http://www.curagen.com/
